Evaluating Treatment from the Point of View of the Patient - PROs (Patient-Reported Outcomes)

被引：6

作者：

Boerdlein-Wahl, Inge ^{[1
]}

Hilpert, Felix ^{[2
]}

Kohlmann, Thomas ^{[3
]}

机构：

[1] Mamazone Sudw, Ladenburg, Germany

[2] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany

[3] Inst Community Med, Abt Methoden Community Med, Greifswald, Germany

来源：

ONKOLOGIE | 2009年 / 32卷

关键词：

Patient-reported outcomes; Clinician-reported outcomes; Health-related quality of life; Ovarian cancer; Coping strategy; ADVANCED OVARIAN-CANCER; 1ST-LINE TREATMENT; CARBOPLATIN/PACLITAXEL; CHEMOTHERAPY; LIFE;

D O I：

10.1159/000215717

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The patient's own evaluation of treatment can simplify communication between the patient and the treating physician; it provides additional important information for therapy control and improves patient compliance. Patient-reported outcomes (PROs) have already been examined in clinical studies among patients suffering from advanced ovarian cancer for a long time now and have made an important contribution with respect to the definition of a recognized standard of treatment for first-line therapy. This article describes the significance of PROs from the point of view of a social scientist, a gynaecologist, and an affected patient.

引用

页码：18 / 20

页数：3

共 5 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].

CELLA, DF ;

TULSKY, DS ;

GRAY, G ;

SARAFIAN, B ;

LINN, E ;

BONOMI, A ;

SILBERMAN, M ;

YELLEN, SB ;

WINICOUR, P ;

BRANNON, J ;

ECKBERG, K ;

LLOYD, S ;

PURL, S ;

BLENDOWSKI, C ;

GOODMAN, M ;

BARNICLE, M ;

STEWART, I ;

MCHALE, M ;

BONOMI, P ;

KAPLAN, E ;

TAYLOR, S ;

THOMAS, CR ;

HARRIS, J .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579

[3] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].

du Bois, A ;

Lück, HJ ;

Meier, W ;

Adams, HP ;

Möbus, V ;

Costa, S ;

Bauknecht, T ;

Richter, B ;

Warm, M ;

Schröder, W ;

Olbricht, S ;

Nitz, U ;

Jackisch, C ;

Emons, G ;

Wagner, U ;

Kuhn, W ;

Pfisterer, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330

[4] Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy -: a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group [J].

Hilpert, F ;

Stähle, A ;

Tomé, O ;

Burges, A ;

Rossner, D ;

Späthe, K ;

Heilmann, V ;

Richter, B ;

du Bois, A .

SUPPORTIVE CARE IN CANCER, 2005, 13 (10) :797-805

[5] Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer -: a study by the AGO OVAR Germany [J].

Hilpert, F. ;

du Bois, A. ;

Greimel, E. R. ;

Hedderich, J. ;

Krause, G. ;

Venhoff, L. ;

Loibl, S. ;

Pfisterer, J. .

ANNALS OF ONCOLOGY, 2007, 18 (02) :282-287

← 1 →